Somatic mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma receptor tyrosine kinase (ALK), proto-oncogene tyrosine-protein kinase ROS (ROS) and RET proto-oncogene (RET) have been nominated as solid predictive biomarkers and attractive drug targets in NSCLC [5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.